$5.15
In the last 1 year, Novo Nordisk A/s has given 43.0% return, outperforming this stock by 18.9%
In the last 3 years, Novo Nordisk A/s has given 139.6% return, outperforming this stock by 224.5%
1.55%
Downside
Day's Volatility :3.61%
Upside
2.09%
54.17%
Downside
52 Weeks Volatility :65.55%
Upside
24.82%
Period | Oric Pharmaceuticals | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 20.66% | 4.7% | -0.2% |
6 Months | 59.63% | -5.8% | -1.5% |
1 Year | 24.11% | 3.6% | -1.7% |
3 Years | -85.2% | 26.6% | 20.6% |
Market Capitalization | 248.5M |
Book Value | $4.5 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -2.09 |
Wall Street Target Price | 13.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -22.22% |
Return On Equity TTM | -39.44% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -88.2M |
Diluted Eps TTM | -2.09 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.17 |
EPS Estimate Next Year | -2.09 |
EPS Estimate Current Quarter | -0.54 |
EPS Estimate Next Quarter | -0.57 |
What analysts predicted
Upside of 162.14%
Sell
Neutral
Buy
Oric Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Oric Pharmaceuticals | 0.0% | 59.63% | 24.11% | -85.2% | -80.05% |
![]() Moderna, Inc. | -4.5% | -24.34% | -1.71% | 107.99% | 571.72% |
![]() Regeneron Pharmaceuticals, Inc. | 0.07% | 1.03% | 31.18% | 23.66% | 140.46% |
![]() Novo Nordisk A/s | -5.39% | 23.69% | 43.02% | 139.56% | 255.68% |
![]() Seagen, Inc. | -2.64% | 47.69% | 39.68% | 30.74% | 191.76% |
![]() Vertex Pharmaceuticals Incorporated | -4.99% | 5.85% | 30.48% | 22.79% | 123.76% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Oric Pharmaceuticals | NA | NA | NA | -2.17 | -0.39 | -0.22 | 0.0 | 4.5 |
![]() Moderna, Inc. | 10.82 | 10.88 | 0.0 | -1.74 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 20.15 | 20.15 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Novo Nordisk A/s | 41.07 | 41.07 | 2.03 | 4.99 | 0.84 | 0.23 | 0.01 | 4.44 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.89 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 25.51 | 25.51 | 0.41 | 14.57 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Oric Pharmaceuticals | Buy | $248.5M | -80.05% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $47.6B | 571.72% | 10.82 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $81.0B | 140.46% | 20.15 | 33.81% |
![]() Novo Nordisk A/s | Buy | $356.5B | 255.68% | 41.07 | 32.47% |
![]() Seagen, Inc. | Hold | $36.5B | 191.76% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $85.1B | 123.76% | 25.51 | 35.4% |
FMR Inc
Column Group LLC
EcoR1 Capital, LLC
Alkeon Capital Management, LLC
Millennium Management LLC
Suvretta Capital Management, LLC
Oric Pharmaceuticals’s price-to-earnings ratio stands at None
Read Moreoric pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. its lead product candidate is oric-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. the company's second product candidate is oric-533, an orally bioavailable small molecule inhibitor of cd73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. it is also developing multiple precision medicines targeting other cancer resistance mechanisms. the company was founded in 2014 and is headquartered in south san francisco, california.
Organization | Oric Pharmaceuticals |
Employees | 88 |
CEO | Dr. Richard A. Heyman Ph.D. |
Industry | Health Technology |
Madison Square Garden Entertainment Corp
$38.13
+3.81%
Quadro Acquisition One Corp
$10.43
+0.0%
Cambria Shareholder Yield Etf
$58.91
-0.37%
Qurate Retail Inc
$6.20
+4.38%
First Trust Enhanced Equity Income Fund
$17.40
+0.17%
Invesco S&p Smallcap 600® Pure Value Etf
$91.43
-1.2%
Mirion Technologies Inc
$8.00
-2.08%
Fulgent Genetics Inc
$38.04
-4.01%
Kinetik Holdings Inc
$32.84
-2.06%